Protein Kinase Inhibitors: all 15,278 studies that test it

Page 42 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• A Study of Abemaciclib in Healthy ParticipantsCompletedNCT02672423Phase 1Results posted
• Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast CancerCompletedNCT02668666Phase 2Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted
• Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
• Influence of Bosentan on the Pharmacokinetics of NintedanibCompletedNCT02667704Phase 1Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2Results posted
• Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial CancerCompletedNCT02657928Phase 2Results posted
• A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerCompletedNCT02657551Phase 2Results posted
• BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT02657486Not applicableResults posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2Results posted
• Phase II Study of Perindopril and Regorafenib in mCRCCompletedNCT02651415Phase 2Results posted
• Single-agent Cobimetinib for Adults With Histiocytic DisordersCompletedNCT02649972Phase 2Results posted
• Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line TherapyCompletedNCT02649387Phase 2Results posted
• Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa LoaTerminatedNCT02644525Phase 2Results posted
• First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With ChemotherapyCompletedNCT02644278Phase 1Results posted
• SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesTerminatedNCT02644122Phase 2Results posted
• Ibrutinib as Neoadjuvant Therapy in Localized Prostate CancerCompletedNCT02643667Phase 2Results posted
• Aging Mammary Stem Cells and Breast Cancer PreventionTerminatedNCT02642094Phase 2Results posted
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02642042Phase 2Results posted
• Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseCompletedNCT02640755Phase 1Results posted
• Eribulin and Lenvatinib in Advanced Solid TumorsCompletedNCT02640508Phase 2Results posted
• Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedNCT02639910Phase 2Results posted
• Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid TumorsCompletedNCT02639546Phase 1/2Results posted
• Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue SarcomasCompletedNCT02636725Phase 2Results posted
• Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 MutationTerminatedNCT02634827Phase 2Results posted
• Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast CancerCompletedNCT02632045Phase 2Results posted
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaCompletedNCT02631590Phase 2Results posted
• Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCompletedNCT02630693Phase 2Results posted
• Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesTerminatedNCT02629692Phase 1/2Results posted
• A Study of LY3337641 in Rheumatoid ArthritisTerminatedNCT02628028Phase 2Results posted
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3Results posted
• A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3Results posted
• Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02627443Phase 1Results posted
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)TerminatedNCT02626455Phase 3Results posted
• Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)CompletedNCT02626026Phase 1Results posted
• A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy ParticipantsCompletedNCT02625259Phase 1Results posted
• 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT02624700Phase 2Results posted
• Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibCompletedNCT02621047Phase 1Results posted
• Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedNCT02616393Phase 2Results posted
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedNCT02614794Phase 2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial CancerTerminatedNCT02612194Phase 2Results posted
• BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic CancerTerminatedNCT02608229Phase 1Results posted
• A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyTerminatedNCT02607124Phase 1/2Results posted
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
• Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingCompletedNCT02604511Phase 2Results posted
• Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibCompletedNCT02604342Phase 3Results posted
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaTerminatedNCT02601209Phase 1/2Results posted
• Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed AppropriateCompletedNCT02600923Phase 3Results posted
• Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsCompletedNCT02599324Phase 1/2Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Phase 2Results posted
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung FibrosisCompletedNCT02597933Phase 3Results posted
• Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02595892Phase 2Results posted
• Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLICompletedNCT02593539Phase 2Results posted
• Efficacy Study Of Tofacitinib In Pediatric JIA PopulationCompletedNCT02592434Phase 3Results posted
• Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) AmyloidosisTerminatedNCT02590588Phase 2Results posted
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsActive, not recruitingNCT02589522Phase 1Results posted
• A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedNCT02588261Phase 3Results posted
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
• Study of INCB053914 in Subjects With Advanced MalignanciesTerminatedNCT02587598Phase 1/2Results posted
• Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial HypertensionCompletedNCT02587325Phase 1Results posted
• A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2Results posted
• TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast CancerCompletedNCT02586675Phase 1Results posted
• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedNCT02584647Phase 1/2Results posted
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT02583893Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaCompletedNCT02581930Phase 2Results posted
• Axitinib Given on an Individualized Schedule for Metastatic Renal Cell CancerCompletedNCT02579811Phase 2Results posted
• Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyCompletedNCT02579616Phase 2Results posted
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedNCT02579603Phase 4Results posted
• A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02576938Phase 2Results posted
• MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular CarcinomaTerminatedNCT02575339Phase 1/2Results posted
• Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT02575300Phase 2Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Relative Bioavailability of 2 Oral Formulations of NintedanibCompletedNCT02572752Phase 1Results posted
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
• Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)TerminatedNCT02568683Phase 1/2Results posted
• Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is RecurrentCompletedNCT02568449Phase 2Results posted
• A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled AsthmaCompletedNCT02567708Phase 2Results posted
• Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaCompletedNCT02567656Phase 1Results posted
• Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT02567422Phase 1Results posted
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT02565901Phase 1/2Results posted
• Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCompletedNCT02562898Phase 1/2Results posted
• LEO 124249 Ointment in the Treatment of Alopecia AreataCompletedNCT02561585Phase 2Results posted
• Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialCompletedNCT02561455Phase 1/2Results posted
• Trial of TRC105 and Sorafenib in Patients With HCCCompletedNCT02560779Phase 1/2Results posted
• Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedNCT02560025Phase 2Results posted
• Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
• Bioavailability of Belumosudil (KD025) in Healthy Male SubjectsCompletedNCT02557139Phase 1Results posted
• Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma ExpressionTerminatedNCT02555189Phase 1/2Results posted
• A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)TerminatedNCT02553330Phase 2Results posted
• MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedNCT02551055Phase 1Results posted
• BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group StudyTerminatedNCT02550743Phase 1Results posted
• Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial CancerCompletedNCT02549989Phase 2Results posted

← Protein Kinase Inhibitors overview